Novocuff, a Mountain View, CA-based medical device company, raised $26M in Series A funding.
The round was led by AXA IM Alts with participation from Laerdal Million Lives Fund, and continued support from existing investors and new investors Laborie, RH Capital, Avestria Ventures and March of Dimes. In conjunction with the closing of the Series A financing, Curt LaBelle, Head of Healthcare Private Equity at AXA IM Alts, Lilly deSouza Burr, Vice President Global Health Investing at AXA IM Alts, and Becca Shmukler, Principal at the Laerdal Million Lives Fund, have joined Novocuff’s Board of Directors, which also includes Shacey Petrovic as Chair of the Board.
The company intends to use the funds to commence a multi-center U.S. pivotal clinical trial in early 2025.
Led by Donald Lee (COO) & Amelia Degenkolb (CEO), Novocuff is a medical device company dedicated to improving pregnancy outcomes and reducing preterm births caused by PPROM and cervical shortening. Preterm birth is the leading cause of death for infants under the age of one. According to the World Health Organization (WHO), preterm birth complications were responsible for approximately 1 million deaths in 2020.
The Novocuff Cervical Control System (CCS) has been designed as a simple device to address the complex problems associated with the preterm conditions of PPROM and short cervix.
FinSMEs
17/07/2024